GSK's messenger RNA vaccine for seasonal influenza is designed to prompt an immune response to two proteins on the surface of the virus. That could be an advantage over Moderna's recently approved mRNA flu shot, which addresses just one of those proteins.
GSK's messenger RNA vaccine for seasonal influenza is designed to prompt an immune response to two proteins on the surface of the virus.
That could be an advantage over Moderna's recently approved mRNA flu shot, which addresses just one of those proteins.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
GSK's messenger RNA vaccine for seasonal influenza is designed to prompt an immune response to two proteins on the surface of the virus. That could be an advantage over Moderna's recently approved mRNA flu shot, which addresses just one of those proteins.
Open the app view to save this story, compare related coverage, and continue from the same source.